| Benjamin David Pe, MD | |
|
1175 Carondelet Dr, Richland, WA 99354-3300 | |
| (509) 943-9104 | |
| Not Available |
| Full Name | Benjamin David Pe |
|---|---|
| Gender | Male |
| Speciality | Psychiatry |
| Experience | 31 Years |
| Location | 1175 Carondelet Dr, Richland, Washington |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1871698936 | NPI | - | NPPES |
| 8214835 | Medicaid | WA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | MD00027679 (Washington) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Lourdes Hospital Llc | 1850642562 | 38 |
News Archive
They were the ancient Maya of Mexico's Yucatan Peninsula, who will be honored for this tasty contribution on Feb. 14 at the University of North Carolina at Chapel Hill.
Mayo Clinic researchers have identified an immune system deficiency whose presence shows someone is up to four times likelier to die than a person without it. The glitch involves an antibody molecule called a free light chain; people whose immune systems produce too much of the molecule are far more likely to die of a life-threatening illness such as cancer, diabetes and cardiac and respiratory disease than those whose bodies make normal levels. The study is published in the June issue of Mayo Clinic Proceedings.
More than a quarter of otherwise healthy six-year-old children may have metabolic risk factors that put them at increased risk for cardiovascular disease, according to results from an Acta Paediatrica study.
From Alzheimer's to obesity, life can change dramatically if you discover you have a genetic risk of disease. Now, a new study from the Australian Centre for Precision Health, University of South Australia is challenging these predispositions, showing that some of the genes traditionally labelled as 'bad' are not always what they seem.
BeiGene (Beijing), Co., Ltd., today announced dose administration for the first patient in a Phase 1 study of BGB-283 in patients with B-RAF or K-RAS mutations. BGB-283 is an investigational, oral, selective, potent second generation inhibitor of B-RAF, making it a targeted therapeutic candidate to potentially treat and bring benefit to patients with cancers that harbor BRAF mutations and/or aberrations in the RAS-MAPK (mitogen-activated protein kinase) pathway.
› Verified 7 days ago
| Entity Name | Lourdes Hospital Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659861060 PECOS PAC ID: 1850642562 Enrollment ID: O20181113000853 |
News Archive
They were the ancient Maya of Mexico's Yucatan Peninsula, who will be honored for this tasty contribution on Feb. 14 at the University of North Carolina at Chapel Hill.
Mayo Clinic researchers have identified an immune system deficiency whose presence shows someone is up to four times likelier to die than a person without it. The glitch involves an antibody molecule called a free light chain; people whose immune systems produce too much of the molecule are far more likely to die of a life-threatening illness such as cancer, diabetes and cardiac and respiratory disease than those whose bodies make normal levels. The study is published in the June issue of Mayo Clinic Proceedings.
More than a quarter of otherwise healthy six-year-old children may have metabolic risk factors that put them at increased risk for cardiovascular disease, according to results from an Acta Paediatrica study.
From Alzheimer's to obesity, life can change dramatically if you discover you have a genetic risk of disease. Now, a new study from the Australian Centre for Precision Health, University of South Australia is challenging these predispositions, showing that some of the genes traditionally labelled as 'bad' are not always what they seem.
BeiGene (Beijing), Co., Ltd., today announced dose administration for the first patient in a Phase 1 study of BGB-283 in patients with B-RAF or K-RAS mutations. BGB-283 is an investigational, oral, selective, potent second generation inhibitor of B-RAF, making it a targeted therapeutic candidate to potentially treat and bring benefit to patients with cancers that harbor BRAF mutations and/or aberrations in the RAS-MAPK (mitogen-activated protein kinase) pathway.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Benjamin David Pe, MD 1175 Carondelet Dr, Richland, WA 99354-3300 Ph: (509) 943-9104 | Benjamin David Pe, MD 1175 Carondelet Dr, Richland, WA 99354-3300 Ph: (509) 943-9104 |
News Archive
They were the ancient Maya of Mexico's Yucatan Peninsula, who will be honored for this tasty contribution on Feb. 14 at the University of North Carolina at Chapel Hill.
Mayo Clinic researchers have identified an immune system deficiency whose presence shows someone is up to four times likelier to die than a person without it. The glitch involves an antibody molecule called a free light chain; people whose immune systems produce too much of the molecule are far more likely to die of a life-threatening illness such as cancer, diabetes and cardiac and respiratory disease than those whose bodies make normal levels. The study is published in the June issue of Mayo Clinic Proceedings.
More than a quarter of otherwise healthy six-year-old children may have metabolic risk factors that put them at increased risk for cardiovascular disease, according to results from an Acta Paediatrica study.
From Alzheimer's to obesity, life can change dramatically if you discover you have a genetic risk of disease. Now, a new study from the Australian Centre for Precision Health, University of South Australia is challenging these predispositions, showing that some of the genes traditionally labelled as 'bad' are not always what they seem.
BeiGene (Beijing), Co., Ltd., today announced dose administration for the first patient in a Phase 1 study of BGB-283 in patients with B-RAF or K-RAS mutations. BGB-283 is an investigational, oral, selective, potent second generation inhibitor of B-RAF, making it a targeted therapeutic candidate to potentially treat and bring benefit to patients with cancers that harbor BRAF mutations and/or aberrations in the RAS-MAPK (mitogen-activated protein kinase) pathway.
› Verified 7 days ago
Peter Anthony Rosales, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 1175 Carondelet Dr, Richland, WA 99354 Phone: 509-943-9104 Fax: 509-946-7206 | |
Jose Emilio Cardell, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 1175 Carondelet Dr, Richland, WA 99354 Phone: 509-943-9104 | |
Daniel W. Stowens, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 750 Swift Blvd Ste 15, Richland, WA 99352 Phone: 509-392-4138 Fax: 253-444-0270 | |
Mr. Hardildar Singh Gill, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1175 Carondelet Drive, Richland, WA 99352 Phone: 509-943-9104 | |
Dr. Farrukh H Hashmi, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1175 Carondelet Dr, Richland, WA 99354 Phone: 509-943-7215 Fax: 509-943-7206 | |
Dr. Eduardo Smith Singares, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 888 Swift Blvd, Richland, WA 99352 Phone: 509-946-4611 Fax: 509-942-2812 | |
Cheta Nand, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1445 Spaulding Ave Ste 301, Richland, WA 99352 Phone: 509-737-1447 Fax: 509-737-1553 |